A Phase 3 interventional study of Crinecerfont and Placebo in Congenital Adrenal Hyperplasia, sponsored by Neurocrine Biosciences. Active, not recruiting at 70 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences — 2 open to participants now, 5 under way, 2 of them phase 3. Adrenal Hyperplasia, Congenital · Neurocrine Biosciences.
Among the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, this one has the largest enrollment, is the only one that started in 2020, is one of 6 in phase 3, and was the 11th registered.
101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.
Browse Adrenal Hyperplasia, Congenital studies →2 of the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences are open now, in 1 country. Recruiting first, the newest first:
Neurocrine Switzerland GmbH · Sites in United States
Ages 3 mo–47 mo
Neurocrine Biosciences
Ages 18–65
By country, each count listing its studies:
Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 6
First in 2007; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 37 across 50 interventional studies indexed under Adrenal Hyperplasia, Congenital.
Median enrollment 24 across the 16 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo capsule, administered orally, twice daily for 24 weeks, followed by active treatment with crinecerfont for at least 1 year.
Drug: Crinecerfont · Drug: Placebo
Crinecerfont capsule, administered orally, twice daily for 24 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 1 year.
Drug: Crinecerfont
CRF type 1 receptor antagonist
Also known as: NBI-74788, Crenessity
Non-active dosage form
Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24
Least square (LS) mean and standard error (SE) were calculated using analysis of covariance (ANCOVA) model.
Time frame: Baseline, Week 24
Change From Baseline in Serum Androstenedione at Week 4
Time frame: Baseline, Week 4
Number of Participants Who Achieved a Reduction to Physiologic Glucocorticoid Dose While Maintaining Androstenedione Control at Week 24
Time frame: Week 24
Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in Body Weight at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Percent Total Fat Mass at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Serum 17-hydroxyprogesterone (17-OHP) at Week 4
Time frame: Baseline, Week 4
Change From Baseline in Blood Pressure at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Glucose Tolerance at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Waist Circumference at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Menstrual Regularity at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Testicular Adrenal Rest Tumor (TART) Volume at Week 24
Time frame: Baseline, Week 24
| Milestone | Placebo | Crinecerfont |
|---|---|---|
| Started | 60 | 122 |
| Received at least 1 dose of study drug | 59 | 122 |
| Completed | 57 | 117 |
| Not completed | 3 | 5 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | Placebo | Crinecerfont |
|---|---|---|
| Started | 57 | 117 |
| Received at least 1 dose of study drug | 57 | 117 |
| Completed | 22 | 57 |
| Not completed | 35 | 60 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Ongoing in the study | 34 | 58 |
Least square (LS) mean and standard error (SE) were calculated using analysis of covariance (ANCOVA) model.
| percent change | Placebo | Crinecerfont |
|---|---|---|
| Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24 | -10.300 ± 3.247 | -27.322 ± 2.418 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Baseline up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Period: Placebo | 0/60 (0%) | 0/59 (0%) | 39/59 (66.1%) |
| DB Period: Crinecerfont | 0/122 (0%) | 4/122 (3.3%) | 76/122 (62.3%) |
| Event | DB Period: Placebo | DB Period: Crinecerfont |
|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 0/59 | 1/122 |
| Groin abscessInfections and infestations | 0/59 | 1/122 |
| CellulitisInfections and infestations | 0/59 | 1/122 |
| Adrenocortical insufficiency acuteEndocrine disorders | 0/59 | 1/122 |
| PresyncopeNervous system disorders | 0/59 | 1/122 |
| Event | DB Period: Placebo | DB Period: Crinecerfont |
|---|---|---|
| FatigueGeneral disorders | 9/59 | 30/122 |
| HeadacheNervous system disorders | 9/59 | 19/122 |
| Coronavirus infectionInfections and infestations | 5/59 | 17/122 |
| NasopharyngitisInfections and infestations | 8/59 | 6/122 |
| Upper respiratory tract infectionInfections and infestations | 7/59 | 11/122 |
| PyrexiaGeneral disorders | 6/59 | 7/122 |
| DiarrhoeaGastrointestinal disorders | 5/59 | 10/122 |
| NauseaGastrointestinal disorders | 5/59 | 10/122 |
| VomitingGastrointestinal disorders | 5/59 | 6/122 |
| AnxietyPsychiatric disorders | 5/59 | 4/122 |
Full Analysis Set included all randomized participants.
| Age, Continuous(years) | Placebo | Crinecerfont | Total |
|---|---|---|---|
| Mean | 29.8 ± 10.17 | 31.3 ± 9.82 | 30.8 ± 9.93 |
| Sex: Female, Male(Participants) | Placebo | Crinecerfont | Total |
|---|---|---|---|
| Female | 29 | 61 | 90 |
| Male | 31 | 61 | 92 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Crinecerfont | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 6 | 14 |
| Not Hispanic or Latino | 52 | 116 | 168 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Crinecerfont | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 5 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 57 | 107 | 164 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 2 | 6 | 8 |
| Daily Glucocorticoid Dose(milligrams (mg)/day) | Placebo | Crinecerfont | Total |
|---|---|---|---|
| Mean | 32.06 ± 32.06 | 32.44 ± 9.24 | 32.31 ± 9.30 |
| Daily Glucocorticoid Dose Adjusted for Body Surface Area(mg/square meter (m^2)/day) | Placebo | Crinecerfont | Total |
|---|---|---|---|
| Mean | 17.91 ± 5.45 | 17.45 ± 4.54 | 17.60 ± 4.85 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Jul 2023, 31 months.
Results were first posted in Feb 2025, 1 year 6 months after primary completion. A results delay was requested in Jul 2024.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crinecerfont
Adrenal Hyperplasia, Congenital →